Cargando…

Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer

SIMPLE SUMMARY: There is an urgent need to improve the therapeutic options in pancreatic cancer. In this study, we assessed the ability of two standard-of-care chemotherapeutic regimens to modulate the levels of PD-L1 mRNA isolated from plasma-derived microvesicles (MVs) of patients with pancreatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Re, Marzia, Vivaldi, Caterina, Rofi, Eleonora, Salani, Francesca, Crucitta, Stefania, Catanese, Silvia, Fontanelli, Lorenzo, Massa, Valentina, Cucchiara, Federico, Fornaro, Lorenzo, Capuano, Annalisa, Fogli, Stefano, Vasile, Enrico, Danesi, Romano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345069/ https://www.ncbi.nlm.nih.gov/pubmed/34359638 http://dx.doi.org/10.3390/cancers13153738

Ejemplares similares

Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Vivaldi, Caterina, et al.
Publicado: (2016)

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
por: Del Re, Marzia, et al.
Publicado: (2017)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
por: Del Re, Marzia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?
por: Vivaldi, Caterina, et al.
Publicado: (2020)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
por: Cucchiara, Federico, et al.
Publicado: (2020)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
por: Bekaii-Saab, Tanios, et al.
Publicado: (2023)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
por: Kamata, Ken, et al.
Publicado: (2023)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo
por: Saito, Nobuhiro, et al.
Publicado: (2018)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019)

Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
por: Winer, Arthur, et al.
Publicado: (2021)

A case of metastatic NUT carcinoma with prolonged response on gemcitabine and nab‐paclitaxel
por: Patel, Shetal A., et al.
Publicado: (2021)

Fibroblast inhibition by tocilizumab enabled gemcitabine/nab‐paclitaxel rechallenge for pancreatic cancer
por: Mitsunaga, Shuichi, et al.
Publicado: (2023)

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
por: Del Re, Marzia, et al.
Publicado: (2019)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
por: Zhang, Feng, et al.
Publicado: (2022)

Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients
por: Catanese, Silvia, et al.
Publicado: (2021)

Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
por: Gharaibeh, M, et al.
Publicado: (2015)

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2019)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
por: Ceccon, Garry, et al.
Publicado: (2020)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2018)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution
por: Cesario, Silvia, et al.
Publicado: (2023)

Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer
por: Agostini, Antonio, et al.
Publicado: (2023)

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
por: Arrigoni, Elena, et al.
Publicado: (2018)

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors
por: Bauer, Todd M, et al.
Publicado: (2018)

Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report
por: Comito, Francesca, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jjs7487logsdb5hiss6hhhd0g5